Evidence map›Paper›PMID 41393707›Full record

ArticleCureus2025

Stiff-Person Syndrome: Diagnostic and Therapeutic Insights Into a Rare Autoimmune Neurological Disorder.

Taoufik Boubga, Yahya Naji, Nawal Adali

Abstract readCase Reports
In one paragraph

Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Taoufik BoubgaDepartment of Neurology, Military Hospital Oued Eddahab, Agadir, MAR.
Yahya NajiDepartment of Neurology, Agadir Medical School, Ibn Zohr University, Agadir, MAR.
Nawal AdaliDepartment of Neurology, Faculty of Medicine and Pharmacy of Agadir, Ibn Zohr University, Agadir, MAR.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Stiff-person syndrome (SPS) is a rare autoimmune neurological disorder that is frequently underrecognized due to overlapping musculoskeletal and neuropsychiatric symptoms, leading to delays in diagnosis. We report a 56-year-old Moroccan woman with a seven-year history of progressive lumbar stiffness and painful, stimulus-sensitive spasms extending to both lower limbs, resulting in marked functional limitation and falls. Serum testing showed markedly elevated anti-glutamic acid decarboxylase (anti-GAD) antibodies (greater than 20,000 U/mL), while the spine MRI revealed only mild degenerative changes, and whole-body positron emission tomography excluded malignancy. Symptomatic therapy with pregabalin and baclofen provided partial relief. Intravenous immunoglobulin was administered at a total dose of 2 g/kg over five days, yielding a substantial reduction in stiffness and spasm frequency; at one month, she demonstrated improved mobility and greater independence. Rituximab was proposed for long-term disease control given disease severity and seropositivity. This case underscores the diagnostic value of anti-GAD testing when imaging is unrevealing and highlights that timely initiation of immunotherapy, together with symptomatic agents and rehabilitation, can meaningfully improve outcomes. A multidisciplinary strategy is essential for sustained functional recovery and quality of life in SPS.

Indexed as

anti-gad antibodiesautoimmune neurologycase reportintravenous immunoglobulin (ivig)rituximabstiff-person syndrome

Identifiers

PMID41393707
PMCPMC12701777

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.